Cervical cancer articles from across Nature Portfolio

A 10-year follow-up study of the HPV-16/18 bivalent vaccine shows that vaccination alters the natural history of high-risk HPV types, resulting in reduced HPV-16/18 infections while HPV-52 infections persist with decreased clearance and increased progression. The study shows that vaccinated populations have distinct HPV epidemiological profiles, indicating that current cervical cancer screening algorithms may be suboptimal.

This study reveals that the TRPC3 channel is essential for HPV-driven cervical cancer. TRPC3 promotes malignant transformation by regulating the RASA4/MAPK pathway and EMT. Targeting TRPC3 could be a new therapeutic strategy.

Pre-treatment dual immune checkpoint blockade in cervical cancer remains understudied. In this trial, the authors show that neoadjuvant immune checkpoint blockade enhances immune activation and correlates with improved response to subsequent chemoradiation in patients with cervical carcinoma.

The antibody–drug conjugate (ADC) tisotumab vedotin resulted in improved progression-free and overall survival, leading to FDA approval and a new treatment option for patients.